Articles de revue sur le cancer du poumon - Dernièr es parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer du poumon (6 février 2008):

Inflammation and lung cancer: roles of reactive oxygen/nitrogen
species.
Azad N, Rojanasakul Y, Vallyathan V.
J Toxicol Environ Health B Crit Rev. 2008 Jan;11(1):1-15.

Molecularly tailored adjuvant chemotherapy for resected non-small cell
lung cancer: a time for excitement and equipoise.
Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG.
J Thorac Oncol. 2008 Jan;3(1):84-93.

Stereotactic body radiation therapy: a comprehensive review.
Chang BK, Timmerman RD.
Am J Clin Oncol. 2007 Dec;30(6):637-44.

Peroxiredoxins in the lung with emphasis on peroxiredoxin VI.
Schremmer B, Manevich Y, Feinstein SI, Fisher AB.
Subcell Biochem. 2007;44:317-44.

Non-receptor tyrosine kinase inhibitors in lung cancer.
Hahn O, Salgia R.
Anticancer Agents Med Chem. 2007 Nov;7(6):633-42.

18Fluorodeoxyglucose positron emission tomography in the diagnosis and
staging of lung cancer: a systematic review.
Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C,
Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's
Program in Evidence-Based Care.
J Natl Cancer Inst. 2007 Dec 5;99(23):1753-67.

Gemcitabine and carboplatin in combination for the treatment of
advanced, metastatic, non-small cell lung cancer.
Nagel S, Califano R, Thatcher N, Blackhall F.
Expert Opin Pharmacother. 2007 Dec;8(18):3265-75.

Molecular profiling for the identification of new biomarkers in
smokers and cancer patients.
Albermann K, Lang S, Zeidler R.
Cancer Genomics Proteomics. 2007 Sep-Oct;4(5):349-58.

Cancer targeting using tumor suppressor genes.
Chada S, Menander KB, Bocangel D, Roth JA, Ramesh R.
Front Biosci. 2008 Jan 1;13:1959-67.

The impact of genetic markers on the diagnosis of lung cancer: a
current perspective.
Chorostowska-Wynimko J, Szpechcinski A.
J Thorac Oncol. 2007 Nov;2(11):1044-51.

Recent advances with topotecan in the treatment of lung cancer.
O'Brien M, Eckardt J, Ramlau R.
Oncologist. 2007 Oct;12(10):1194-204.

The role of bevacizumab in the treatment of non-small cell lung
cancer: current indications and future developments.
Gridelli C, Maione P, Rossi A, De Marinis F.
Oncologist. 2007 Oct;12(10):1183-93.

Lymph node micrometastases in lung cancer.
Effenberger KE, Sienel W, Pantel K.
Cancer Treat Res. 2007;135:167-75.

New targets for non-small-cell lung cancer therapy.
Alvarez M, Roman E, Santos ES, Raez LE.
Expert Rev Anticancer Ther. 2007 Oct;7(10):1423-37.

Elemene for the treatment of lung cancer.
Rui D, Xiaoyan C, Taixiang W, Guanjian L.
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD006054.

Wnt signaling in stem cells and lung cancer.
He B, Jablons DM.
Ernst Schering Found Symp Proc. 2006;5:27-58.

Potential clinical applications of epothilones: a review of phase II
studies.
Larkin JM, Kaye SB.
Ann Oncol. 2007 Jul;18 Suppl 5:v28-34.

Erlotinib in non-small-cell lung cancer.
Gridelli C, Rossi A, Maione P, Colantuoni G, Del Gaizo F, Ferrara C,
Nicolella D, Guerriero C.
Expert Opin Pharmacother. 2007 Oct;8(15):2579-92.

Induction of BIM is essential for apoptosis triggered by EGFR kinase
inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W.
PLoS Med. 2007 Oct 9;4(10):e294.

Small cell lung cancer: have we made any progress over the last 25
years?
Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC.
Oncologist. 2007 Sep;12(9):1096-104.


(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)